Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEMA-PLAT: Impact of Oral Semaglutide on Platelet Reactivity
2025-522486-29-01Phase 3Authorised
- Sponsor
- ICOT
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), Overweight, obesity and 1 more (2 arms), sponsored by ICOT. Primary endpoint: Change in platelet reactivity by LTA at T3. Planned start Apr 2026; status: authorised.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)Overweightobesitycardiac morbidity
Beyond the preview
Go deeper on 2025-522486-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522486-29-01.